First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

L Albiges; NM Tannir; M Burotto; D McDermott; ER Plimack; P Barthélémy; C Porta; T Powles; F Donskov; S George; CK Kollmannsberger; H Gurney; MO Grimm; Y Tomita; D Castellano; BI Rini; TK Choueiri; D Leung; SS Saggi; CW Lee; MB McHenry; RJ Motzer

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

L Albiges, NM Tannir, M Burotto, D McDermott, ER Plimack, P Barthélémy, C Porta, T Powles, F Donskov, S George, CK Kollmannsberger, H Gurney, MO Grimm, Y Tomita, D Castellano, BI Rini, TK Choueiri, D Leung, SS Saggi, CW LeeMB McHenry, RJ Motzer

Research output: Contribution to journal › Editorial

Original language	American English
Pages (from-to)	442-+
Number of pages	3
Journal	Journal of Urology
Volume	209
Issue number	2
State	Published - Feb 2023

Cite this

Albiges, L., Tannir, NM., Burotto, M., McDermott, D., Plimack, ER., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, CK., Gurney, H., Grimm, MO., Tomita, Y., Castellano, D., Rini, BI., Choueiri, TK., Leung, D., Saggi, SS., ... Motzer, RJ. (2023). First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. Journal of Urology, 209(2), 442-+.

@article{8dfe23298e84401398dd512fc15d4d3f,

title = "First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial",

author = "L Albiges and NM Tannir and M Burotto and D McDermott and ER Plimack and P Barth{\'e}l{\'e}my and C Porta and T Powles and F Donskov and S George and CK Kollmannsberger and H Gurney and MO Grimm and Y Tomita and D Castellano and BI Rini and TK Choueiri and D Leung and SS Saggi and CW Lee and MB McHenry and RJ Motzer",

year = "2023",

month = feb,

language = "American English",

volume = "209",

pages = "442--+",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "2",

}

Albiges, L, Tannir, NM, Burotto, M, McDermott, D, Plimack, ER, Barthélémy, P, Porta, C, Powles, T, Donskov, F, George, S, Kollmannsberger, CK, Gurney, H, Grimm, MO, Tomita, Y, Castellano, D, Rini, BI, Choueiri, TK, Leung, D, Saggi, SS, Lee, CW, McHenry, MB & Motzer, RJ 2023, 'First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial', Journal of Urology, vol. 209, no. 2, pp. 442-+.

TY - JOUR

T1 - First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

AU - Albiges, L

AU - Tannir, NM

AU - Burotto, M

AU - McDermott, D

AU - Plimack, ER

AU - Barthélémy, P

AU - Porta, C

AU - Powles, T

AU - Donskov, F

AU - George, S

AU - Kollmannsberger, CK

AU - Gurney, H

AU - Grimm, MO

AU - Tomita, Y

AU - Castellano, D

AU - Rini, BI

AU - Choueiri, TK

AU - Leung, D

AU - Saggi, SS

AU - Lee, CW

AU - McHenry, MB

AU - Motzer, RJ

PY - 2023/2

Y1 - 2023/2

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000928267800067&DestLinkType=FullRecord&DestApp=WOS

M3 - Editorial

SN - 0022-5347

VL - 209

SP - 442-+

JO - Journal of Urology

JF - Journal of Urology

IS - 2

ER -

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

Other files and links

Fingerprint

Cite this